IRCT20200623047902N14
Not yet recruiting
未知
Bioequivalence study of Famotidine 40 mg tablet manufactured by Sanamed company versus the originator brand in healthy volunteers
Sanamed pharma company0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Sanamed pharma company
- Enrollment
- 24
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18\-28\)
- •Informed consent
- •Age (18\-55 years old)
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Famotidine
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mg tabletIRCT20200105046010N85Tabriz University of Medical Sciences24
Completed
Not Applicable
Bioequivalance study of Famotidine 40 mgIRCT20200513047423N5Fatak chemie pars Pharmacy24
Not yet recruiting
Not Applicable
Bioequivalance study of Famotidine 40 mgSubject: Bioequivalence of Famotidine 40 mg Tablet and Comparison of Pharmacokinetic Parameters with Ratiopham Reference Tablet.IRCT20200513047423N9Iran Daru Pharmaceutical Company24
Recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mg tabletIRCT20210519051345N32Tabriz University of Medical Sciences24
Completed
Not Applicable
Bioequivalence study of Famotidine 40 mg coated tablets of Medava Pharmaceutical Company with Famotidine 40 mg coated tablets of Telomed Pharmaceutical Company of EnglandIRCT20130313012810N18Modava Pharmaceutical Company24